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Tuberculosis (TB) caused by Mycobacterium tuberculo-
sis, remains a major global health concern. According to
the World Health Organization (WHO), TB was respon-
sible for the occurrence of 1.8 million deaths in 2012
[1], and currently represents the main cause of human
death due to a single pathogen. Increasing HIV-TB co-
infections, the emergence of multidrug-resistant (MDR)
[2,3], extensively drug-resistant(XDR) [3,4], and, more
recently, of totally drug resistant strains (TDR) [5] have
increased the need for developing new drugs to treat
TB. Globally, 3,7% of new TB cases and 20% of pre-
viously treated patients are estimated to have MDR-TB
[2] Ideally, novel anti-Tb drugs, should be effective
against the resistant strains, decreasing the length of
treatment thereby improving patients compliance with
lower dose frequency, minimal drug-drug interactions
and reduced toxicity issues [1,3].
Isoniazid (INH) is the most prescribed drug for active
TB and prophylaxis. It has been demonstrated that its
primary target is the M. tuberculosis 2-trans-enoyl-ACP
(CoA)reductase enzyme (inhA) [4]. Furthermore, INH is
s pro-drug, activated by the mycobacterial KatG-encoded
catalase-peroxidase enzyme in the presence of manga-
nese ions, NAD(H) and oxygen [5]. Unfortunately, the
use of INH has been allied to a series of collateral effects,
especially neurotoxic and hepatotoxic side effects [6].
Our group has described a new approach to the rational
design of an INH analogue based on an inorganic group
(a pentacyanoferrate III/II) attached to the nitrogen atom
of the heterocyclic ring of INH, which inhibits the vali-
date target inhA [6,7]. The metal center of the compound
can promote an electron transfer reaction that mimics
the in vitro activation of INH by KatG enzyme. In fact,
our group has also proved that this new compound pen-
tacyano(isoniazid)ferrate(II) (named IQG-607), does not
require the activation by katG or any other enzyme to
bind to its orimary target the M. tuberculosis inhA [7,8];
this profile might help to overcome an important
mechanism of INH-resistance, the missense mutations in
the katG gene. Moreover, our group has demonstrated
that the compound IQG-607 is able to inhibit in vitro
activity of wild-type and INH-resistant I21V,I47T and
S94A M. tuberculosis inhA mutant enzymes more slowly
than INH [8,10]. Slow rates of dissociation are expected
when we intend to reach higher inhibitory effectiveness
and, therefore, the intervals between the doses adminis-
tered to patients can be longer.
Noteworthy, another new compound containing a
pentacionaferrate and an oxadiazole moiety, pentacyano
(2-metil-5-(piridin-4-il)-1,3,4-oxadiazole)ferrate (II),
(named IQG-639) was also found to be able to inhibit
the in vitro activity of wild-type and INH resistant
(S94A) M. tuberculosis inhA enzymes. Other experi-
ments demonstrated that both IQG-607 and IQG-639
were active against culture of M. tuberculosis H37Rv
and two INH-resistant clinical isolates, showing satisfac-
tory efficacy in vitro.
Importantly, we have established toxicological para-
meters in mice to determine the safety of both compounds
and to guide us in the next in vivo tests. Furthermore,90
days repeated-doses toxicological studies in rats revealed a
very favorable outcome for IQG-607 which was also very
active in mouse macrophages infected with M. tuberculo-
sis. It thus appears warranted to examine the potential in
vivo anti-TB activity of these two compounds, IQG-607
and IQG-639. Accordingly, the activity of these com-
pounds was evaluated by using an in vivo murine model
of tuberculosis infection. Swiss mice were infected with
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M. tuberculosis H37Rv strain and IQG-607 and IQG-639
(250mg/kg) were administered during 28 or 56 days. A
dose response study was also performed with IQG-607 at
5, 10, 25, 100, 200 and 250mg/kg. The activity of test com-
pound was compared with that of positive control drug
INH at 25 mg/kg. After either 28 or 56 days of treatment,
both IQG-607 and INH significantly reduced M. tubercu-
losis-induced splenomegaly, and also significantly dimin-
ished the colony forming units (CFU) in both spleens and
lungs. IQG-607 or INH ameliorated the lung macroscopic
aspect, reducing the lung lesions (granuloma like) to a
similar extent [9]. However, IQG-639 was not capable or
significantly modifying any evaluated parameters. In addi-
tion, experiments using early and late controls of infection
revealed a bactericidal activity for IQG-607 in the animal
model of infection. The promising activity of IQG-607 in
M. tuberculosis-infected mice brings the hope that this
compound might represent a good candidate for clinical
development as a new antimycobacterial agent. Experi-
ments to demonstrate efficacy and security in dogs and
mini-pigs are under way.
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